(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria . Approval based on phase 3 studies demonstrating Dupixent signifi ...

According to experts, our gut microbiome and our immune system are connected. And new studies have proven the cellular link ...

For millions of people around the world, asthma is more than just a breathing problem—it is a chronic and often debilitating ...

Food allergies are slowly increasing within first world countries. According to the National Institute of Allergy and ...

Evommune launches mid-stage trials for immune-modulating drugs targeting skin conditions, backed by $115M funding and led by ex-Dermira executives.

Discover natural supplements and practical strategies that can help alleviate seasonal allergy symptoms while reducing ...

The experts recommend 24-hour or “second-generation” antihistamines like cetirizine (Zyrtec) or fexofenadine (Allegra), which ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Some people looking for natural treatments for seasonal allergies are turning to local honey. But there’s limited evidence it ...